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Background. Little is known about the constraints of optimizing health care for prostate cancer survivors in
Alaska primary care.
Objective. To describe the experiences and attitudes of primary care providers within the Alaska Tribal Health
System (ATHS) regarding the care of prostate cancer survivors.
Design. In late October 2011, we emailed a 22-item electronic survey to 268 ATHS primary care providers
regarding the frequency of Prostate Specific Antigen (PSA) monitoring for a hypothetical prostate cancer
survivor; who should be responsible for the patient’s life-long prostate cancer surveillance; who should
support the patient’s emotional and medical needs as a survivor; and providers’ level of comfort addressing
recurrence monitoring, erectile dysfunction, urinary incontinence, androgen deprivation therapy, and emo-
tional needs. We used simple logistic regression to examine the association between provider characteristics
and their responses to the survivorship survey items.
Results. Of 221 individuals who were successfully contacted, a total of 114 responded (52% response rate).
Most ATHS providers indicated they would order a PSA test every 12 months (69%) and believed that,
ideally, the hypothetical patient’s primary care provider should be responsible for his life-long prostate cancer
surveillance (60%). Most providers reported feeling either ‘‘moderately’’ or ‘‘very’’ comfortable addressing
topics such as prostate cancer recurrence (59%), erectile dysfunction (64%), urinary incontinence (63%),
and emotional needs (61%) with prostate cancer survivors. These results varied somewhat by provider
characteristics including female sex, years in practice, and the number of prostate cancer survivors seen in
their practice.
Conclusions. These data suggest that most primary care providers in Alaska are poised to assume the care of
prostate cancer survivors locally. However, we also found that large minorities of providers do not feel
confident in their ability to manage common issues in prostate cancer survivorship, implying that continued
access to specialists with more expert knowledge would be beneficial.
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P
rostate cancer is the most common non-skin cancer
in men in the United States (1). Although the inci-
dence of prostate cancer among Alaska Native
men is lower than the US population, mortality is higher
(2). While white men survive longer than other races
(i.e. AfricanAmerican, Hispanic, and American Indian/
Alaska Native), survival rates for different races are
similar when corrected for grade and stage. The stage at
diagnosis predicts 5-year disease-specific survival rates:
local stage disease, 100%; regional stage, 94%; and
metastatic disease, 31% (3). Many patients with prostate
cancer are asymptomatic at diagnosis and it is recommen-
ded that primary care providers engage in an informed
discussion with their patients as screening does increase
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the number of men diagnosed with non-metastatic, early
disease (4). Furthermore, policy makers have highlighted
the importance of survivorship care, partially managing
consequences of primary treatment in primary care. With
survivorship growing in importance, it is imperative to
know the perceived capacity of primary care providers to
engage in survivorship care.
The Alaska Native Tribal Health System (ATHS)
provides birth to death care for approximately 130,000
Alaska Natives/American Indians residing in the
500,000 square mile state. It is a primarily roadless
state with immense geographic barriers from the Arctic
environment in the north, mountain ranges and moderate
rain forests in the southern part of the state. They also
provide health care for non-Natives when there are no
private options. The ATHS includes physicians located at
the Alaska Native Medical Center (ANMC), a tertiary
care hospital, and 6 regional primary care hospitals. Rural
hospital physicians make a few trips each year to the
villages within the region, while ANMC physicians travel
to regional hospitals to hold specialty clinics. Others
including nurse practitioners and physician assistants
work at ANMC, regional hospitals, and at sub-clinics
located in a few of the larger villages. The primary care
providers in the remote hospitals do not have the network
of support city hospitals provide. They must make
decisions daily on a wide range of medical issues pre-
sented to them and often have insufficient time to provide
on-going support to patients.
Alaska Native men in rural Alaska who are referred
for screening must travel long distances to see ANMC
urology specialists for diagnosis and treatment if an
abnormality is identified. Our previous outreach work
with prostate cancer survivors in Alaska raised issues in
care coordination for these patients. Specialists who are
most skilled are overburdened and hours away. Local
doctors know them well but seemed to have variable
levels of confidence managing symptoms and sequelae
after treatment.
Treatment for prostate cancer involves important
decision-making trade-offs and potential long-term se-
quelae requiring on-going management. Poor patient
provider communication in prostate cancer may result
in lack of informed treatment choices, may lead to care
that does not elicit patient priorities, and may also result
in treatments that are either too aggressive (i.e. result in
functional outcome disparities) or not aggressive enough
(i.e. result in survival disparities). The care of cancer
survivors is an important priority identified by national
bodies such as the National Cancer Institute (NCI),
Institute of Medicine (IOM), and American Cancer
Society (ACS) (57). For patients diagnosed with prostate
cancer, they confront multiple health issues ranging from
cancer surveillance and quality of life concerns following
treatment.
Ideally, the medical care following primary therapy
for prostate cancer would involve multidisciplinary medi-
cal care with urologists, radiation oncologists, medical
oncologists and primary care providers. Caring for sur-
vivors in rural and geographically dispersed contexts with
limited budgets as is the case in the ATHS, however, may
be challenging. In these settings, primary care providers
may serve as an even more important clinical link for
prostate cancer survivors in particular, dealing with a
variety of functional and quality of life concerns. Primary
care providers are often the only link to oncologists due
to geographic constrains and that specialists are only
available in Anchorage and Fairbanks.
Despite NCI, IOM, and ACS priorities to optimize the
care of cancer survivors, little is known about the actual
constraints of doing so in Alaska and specifically in
primary care settings. With limited resources and avail-
ability of specialists and as part of larger collaborations
surrounding care delivery in prostate cancer, ANMC
urologists requested support from the Mayo Clinic on
how to best provide urology consult support services
to regional primary care providers who suspected a
diagnosis or prostate cancer and/or needed to provide
on-going care to Alaska Native men diagnosed with
prostate cancer. Ascertaining the degree of comfort and
identifying potential gaps that primary care providers feel
about prostate cancer survivorship may improve the
quality of care. The purpose of this study was to describe
the experiences and attitudes of primary care providers
within the ATHS regarding the care of prostate cancer
survivors.
Methods
Study participants & data collection
The Mayo Clinic and Alaska Area Institutional Review
Boards approved this study. The research team was
comprised of a general internist, 2 urologists, and cancer
researchers with public health backgrounds. We compiled
a list and obtained email addresses for all primary care
providers (including physicians, nurse practitioners, and
physician assistants) currently practicing in the ATHS.
In some cases, regional hospitals’ lists of provider
employees’ email addresses were not up-to-date. Relia-
bility of email service varies among regional corporations
and some providers use their personal email for work
purposes.
The survey was developed in August 2011 and under-
went pilot testing with a small group of providers com-
prised of 4 general internists, an oncologist, and a family
nurse practitioner. Feedback from providers was used to
reword survey questions and how to incentivize partici-
pation. In preparation for survey distribution, ANMC
Medical Director/Urologists mailed out an introductory
letter notifying all Tribal Health Directors that the survey
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would be distributed to all primary providers within their
facility and to encourage their participation. In late
October 2011, we emailed a link to a 22-item electronic
survey to this sample of providers. Providers who com-
pleted the survey were entered in a raffle to win one of
three gift certificates for a complimentary flight to any
destination within the United States. Providers who did
not respond to the first invitation to participate were sent
up to 3 subsequent reminder messages. Providers who did
not respond after the second email were also sent a paper
version of the electronic survey. We also enlisted the
support of administrative coordinators to help encourage
provider participation at regional sites and included them
in a separate raffle for a complementary flight. The
process and incentive techniques used were drawn from
survey research techniques aimed at reaching a busy
provider population that is often inundated with survey
requests from researchers interested in experiences in a
remote setting.
Survey instrument
The electronic survey instrument for this study was
developed using REDCap electronic data capture tools
hosted at Mayo Clinic (8). REDCap (Research Electronic
Data Capture) is a secure, web-based application de-
signed to support data capture for research studies.
Through an iterative process of literature review, ques-
tion formulation, pilot testing with primary care and spe-
cialty care providers, and subsequent question revision,
our research team developed a 22-item survey containing
questions about ATHS providers’ views on prostate
cancer survivorship. We also included questions about
providers’ demographic characteristics (i.e. age, gender,
practice location, specialty, years in practice, and average
number of patients seen in a clinic day), as well as
providers’ degree of agreement with a statement about
patient adherence: ‘‘The majority of my patients fol-
low through on provider recommendations’’ (‘‘Strongly dis-
agree,’’ ‘‘Somewhat disagree,’’ ‘‘Somewhat agree,’’ ‘‘Strongly
agree’’).
Primary measures
Providers completed 8 questions on survivorship issues
in prostate cancer. These included 5 items that asked
providers to consider a clinical scenario about a married
male patient who ‘‘underwent a radical prostatectomy in
2002 for intermediate risk prostate cancer at age 63 years
(Stage II, Gleason 7, margin negative)’’ who is ‘‘now 72
with diabetes, mild obesity, and hypertension’’ and who,
since his surgery, has ‘‘moderate erectile dysfunction and
mild urinary incontinence.’’ Respondents were asked to
select the frequency with which they would order a PSA
test (‘‘Every 6 months,’’ ‘‘Every 12 months,’’ ‘‘Every 18
months,’’ ‘‘Every 24 months’’), who should be responsible
for the patient’s life-long prostate cancer surveillance
(‘‘Primary care provider,’’ ‘‘Internal medicine provider,’’
‘‘Medical oncologist,’’ ‘‘Urologist’’ or ‘‘Other’’), and who
ideally should support the patient’s emotional health and
medical needs as a prostate cancer survivor (‘‘Onsite
specialist visits,’’ ‘‘Support groups for patients,’’ ‘‘Survi-
vorship clinics,’’ ‘‘Prostate cancer survivor retreats,’’ or
‘‘Other’’).
Respondents were also asked to rate their level of com-
fort addressing prostate cancer recurrence monitoring,
erectile dysfunction, urinary incontinence, and emotional
needs with prostate cancer survivors like the patient in
the clinical scenario (‘‘Not at all comfortable,’’ ‘‘A little
comfortable,’’ ‘‘Moderately comfortable,’’ ‘‘Very comfor-
table’’), their level of confidence in ‘‘managing men
receiving androgen deprivation therapy for prostate
cancer as long as there is a medical oncologist available’’
(same scale as noted above, using ‘‘confident’’ instead of
‘‘comfortable’’), and to estimate the number of prostate
cancer survivors in their regular patient load (‘‘0,’’ ‘‘13,’’
‘‘47,’’ ‘‘8 or more’’).
Analysis
Responses from those providers who completed the paper
version of the survey were manually entered into the
REDCap system. Survey responses were exported from
REDCap into SAS version 9.2 (SAS Institute, Cary, NC),
with which all basic descriptive statistics were calcula-
ted. Bivariate tests of association were performed using
simple logistic regression models. For ease of analysis,
4-point response scales were subsequently dichotomized.
Results
Of the 268 potential respondents, 47 could not be con-
tacted due to undeliverable addresses. Of the remaining
221 participants, a total of 114 providers returned comple-
ted surveys for a response rate of 52% (114/221). Char-
acteristics of respondents are shown in Table I. We were
unable to compare characteristics of non-respondents to
respondents because non-respondent demographic infor-
mation was not available. Provider respondents were
primarily female (64%), practice as physicians (56%), see
more than 11 patients every day (74%), and have been
in practice for more than 10 years (61%). A majority of
respondents also report seeing between 1 and 3 prostate
cancer survivors in their regular patient load (54%), and
agree with the statement ‘‘the majority of my patients
follow through on provider recommendations’’ (67%)
(Table II).
When considering the clinical scenario previously men-
tioned, most ATHS providers would order a PSA test
every 12 months (69%) and believed that, ideally, the
patient’s primary care provider should be responsible for
his life-long prostate cancer surveillance (60%), though
many providers also selected a urologist as the respon-
sible individual (34%). Support groups were selected by
63% of respondents as being the best mode of support for
Alaska Native prostate cancer survivors in primary care
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the patient’s emotional health, while onsite specialist
visits were selected as being the best mode of support for
the patient’s medical needs by the greatest number of
providers (71%).
Regarding topics specific to prostate cancer survi-
vorship care, slightly over half of surveyed providers
indicated that they are either ‘‘not at all’’ or ‘‘a little’’
confident managing men receiving androgen depriva-
tion therapy for prostate cancer even when there is a
medical oncologist available (54%). However, a majority
of providers report feeling either ‘‘moderately’’ or ‘‘very’’
comfortable addressing topics such as prostate cancer
recurrence (59%), erectile dysfunction (64%), urinary
incontinence (63%), and emotional needs (61%) with
prostate cancer survivors.
These results varied somewhat by characteristics of
respondents including sex, years in practice, and the
number of prostate cancer survivors seen in their practice
(Table III). Women were significantly more likely than
men to report being not at all or a little comfortable
monitoring for prostate cancer recurrence (OR 5.3; 95%
CI 2.113.8) and addressing erectile dysfunction (OR 7.3;
95% CI 2.323.0). Compared to newer clinicians with just
05 years of experience, those in practice longer were
significantly less likely to report being not comfortable
monitoring for prostate cancer recurrence (ORs 0.1 &
0.3; 95% CIs 0.030.7, 0.10.9, for 610 years and more
than 10 years in practice, respectively). None of the respon-
dent characteristics included in our analyses were found
to distinguish those lacking confidence in managing men
receiving Androgen Deprivation Therapy (ADT), addres-
sing urinary incontinence, or emotional needs (Table III).
Discussion
In this survey of primary care providers in the ATHS, we
found general agreement about the frequency of post-
treatment PSA monitoring (i.e. every 12 months) and the
preferred individual in charge of life-long prostate cancer
surveillance (i.e. primary care provider) for a hypothetical
prostate cancer survivor described in a clinical scenario.
This finding is important since PSA monitoring is essen-
tial following primary therapy for localized prostate
cancer given the lifelong risk for biochemical recurrence.
Furthermore, primary care providers in a geographic area
with limited access to urologists and radiation oncolo-
gists agreed with PSA monitoring intervals consistent
with clinical guidelines (9). While we had no particular
hypotheses regarding sex, we also found that respon-
dents’ comfort level discussing topics relevant to prostate
cancer survivorship may be associated with it. Conver-
sely, the finding that newer providers are less comfortable
speaks to accumulated experience. If a doctor has taken
care of 12 patients, that may be important, compared to
a seasoned provider. This raises the possibility of tailor-
ing outreach preferentially to subgroups of early career
providers.
Another key aspect of medical care for prostate cancer
survivorship is managing the quality of life issues follow-
ing primary therapy. Indeed, several studies have demon-
strated high rates of treatment-related quality of life issues
following surgery and radiation therapy (10,11). In our
study, we also found relatively high levels of comfort
among ATHS providers in discussing topics such as ere-
ctile dysfunction, urinary incontinence, emotional needs,
and PSA monitoring among prostate cancer survivors.
In our study, we also demonstrate that the 1 area of
medical care where primary care providers expressed the
highest degree of discomfort involved treating men with
Table I. Characteristics of 114 survey respondents as well as
their patient population
Characteristic No. (%)
Sex
Male 41 (36)
Female 73 (64)
Provider type
Physician 64 (56)
Family practice 58 (91)
General practice 1 (2)
Internal medicine 2 (3)
Other 3 (5)
Nurse practitioner 16 (14)
Physician assistant 33 (29)
Other 1 (1)
Years in practice
Less than 1 year 1 (1)
12 years 5 (4)
35 years 19 (17)
610 years 19 (17)
More than 10 years 69 (61)
Average daily no. patients seen
5 or less patients 9 (8)
610 patients 19 (17)
1115 patients 58 (51)
1620 patients 22 (19)
More than 20 patients 5 (4)
In your regular patient load, about how many are
prostate cancer survivors?
0 23 (22)
13 56 (54)
47 14 (14)
8 or more 10 (10)
The majority of my patients follow through on provider
recommendations
Strongly disagree 4 (4)
Somewhat disagree 31 (30)
Somewhat agree 59 (57)
Strongly agree 10 (10)
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primary androgen deprivation therapy. A majority of
respondents stated they had limited or no confidence in
managing primary androgen deprivation therapy and
related long-term sequelae, such as metabolic syndrome,
coronary artery disease to osteoporosis (1215). The use
of primary androgen deprivation therapy following sur-
gery has become increasingly controversial unless used
for overt metastasis or rapidly progressing PSA. It is
therefore understandable that primary care providers
would express less confidence about managing prostate
cancer patients with luteinizing-hormone-releasing hor-
mone (LH-RH) agonists.
This study has several limitations. First, our relati-
vely small sample size limits the generalizability of our
Table II. Attitudes and practices of ATHS providers regarding prostate cancer survivor care
Survey item & response No. (%)
Case study scenario*
If you were monitoring George, how often would you order his
PSA test (assuming he remained asymptomatic)?
Every 6 months 28 (27)
Every 12 months 72 (69)
Every 18 months 0 (0)
Every 24 months 4 (4)
In the ideal situation, who should be responsible for George’s
life-long prostate cancer surveillance?
Primary care provider 62 (60)
Internal medicine provider 1 (1)
Medical oncologist 6 (6)
Urologist 35 (34)
In the ideal situation, which of the following would best support
George’s emotional health as a prostate cancer survivor?
Onsite specialist visits 14 (14)
Support groups for patients 64 (63)
Survivorship clinics 16 (16)
Prostate cancer survivor retreats 8 (8)
Other
In the ideal situation, which of the following would best support
George’s medical needs as a prostate cancer survivor?
Onsite specialist visits 73 (71)
Support groups for patients 6 (6)
Survivorship clinics 14 (14)
Prostate cancer survivor retreats 1 (1)
Other 9 (9)
Issues in prostate cancer survivor care
How confident are you in managing men receiving androgen
deprivation therapy for prostate cancer as long as there
is a medical oncologist available?
Not at all confident 22 (21)
A little confident 34 (33)
Moderately confident 40 (38)
Very confident 8 (8)
Indicate your level of comfort in addressing the following topics
with prostate cancer survivors:
Not at all
comfortable
A little
comfortable
Moderately
comfortable
Very
comfortable
Monitoring for prostate cancer recurrence 7 (7) 36 (35) 39 (38) 22 (21)
Erectile dysfunction 4 (4) 31 (30) 50 (49) 18 (17)
Urinary incontinence 6 (6) 32 (31) 53 (51) 12 (12)
Emotional needs 10 (10) 30 (29) 48 (46) 16 (15)
*Case study: George underwent a radical prostatectomy in 2002 for intermediate risk prostate cancer at age 63 years (Stage II, Gleason 7,
margin negative). He is now 72 with diabetes, mild obesity, and hypertension. Since his surgery, he has moderate erectile dysfunction and
mild urinary incontinence (12 pads per day). He is married. ATHS Alaska Tribal Health System.
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Table III. Unadjusted tests of association
OR (95% CI)
Characteristic
Not at all or a little confident
managing men receiving ADT
for prostate cancer
Not at all or a little comfortable
monitoring for prostate cancer
recurrence
Not at all or a little
comfortable
addressing ED
Not at all or a little
comfortable addressing
urinary incontinence
Not at all or a little
comfortable addressing
emotional needs
Sex
Male 1.0 1.0 1.0 1.0 1.0
Female 3.6 (1.68.3) 5.3* (2.113.8) 7.3* (2.323.0) 3.8 (1.59.9) 1.6 (0.73.7)
Provider type
Physician 1.0 1.0 1.0 1.0 1.0
Non-physician 2.0 (0.94.4) 1.9 (0.84.1) 1.0 (0.42.3) 0.7 (0.31.6) 1.4 (0.63.1)
Years in practice
05 years 1.0 1.0 1.0 1.0 1.0
610 years 1.9 (0.48.0) 0.1 (0.030.7) 0.4 (0.11.7) 0.1 (0.011.0) 0.7 (0.23.0)
More than 10 years 0.8 (0.32.0) 0.3 (0.10.9) 0.7 (0.31.9) 0.9 (0.32.5) 0.8 (0.32.2)
Average daily no. patients seen
10 or less patients 1.0 1.0 1.0 1.0 1.0
1115 patients 0.9 (0.42.4) 0.5 (0.21.4) 1.1 (0.43.0) 1.5 (0.64.2) 2.2 (0.86.0)
1620 patients 0.5 (0.21.8) 0.9 (0.32.9) 0.7 (0.22.7) 1.3 (0.44.6) 2.0 (0.66.9)
More than 20 patients 0.7 (0.16.0) 1.0 (0.18.2) 0.6 (0.17.0) 1.1 (0.114.3) 0.9 (0.110.2)
In your regular patient load, about
how many are prostate cancer
survivors?
0 1.0 1.0 1.0 1.0 1.0
13 0.9 (0.32.5) 0.5 (0.21.3) 0.6 (0.21.7) 0.8 (0.32.2) 1.2 (0.43.1)
47 0.4 (0.11.4) 0.04 (0.010.4) 0.4 (0.11.8) 1.0 (0.33.7) 0.9 (0.23.4)
8 or more 0.3 (0.11.4)    0.2 (0.021.6)
The majority of my patients follow
through on provider
recommendations
Strongly/somewhat disagree 1.0 1.0 1.0 1.0 1.0
Strongly/somewhat agree 0.5 (0.21.1) 0.4 (0.21.0) 0.4 (0.21.0) 0.7 (0.31.6) 0.4 (0.21.0)
*pB0.001.
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findings beyond that of primary care providers in Alaska.
Furthermore, our response rate was moderate, but with a
fairly high number of undeliverable mailings. This could
be due to logistical issues related to the maintenance of
reliable email, lack of updating of provider lists or high
provider turnover rates. If the survey was repeated
elsewhere, the opinions reported may differ; however,
we feel that this is unlikely due to the independent nature
of the ATHS email system and that there were no
significant differences between ‘‘new’’ (i.e. 12 years in
practice) primary care providers and ‘‘experienced’’ (10
or more years in practice) providers and their responses
to the survey. We also chose to design a survey consisting
of primarily close-ended (i.e. forced-choice) questions,
which may have limited our ability to more richly assess
the potential gaps or barriers that primary care providers
in Alaska experience or perceive in their care of prostate
cancer survivors. Further research utilizing mixed meth-
ods or a purely qualitative design may help address this
limitation and shed further light on the experience of
Alaska primary care providers.
Overall, these data suggest that most primary care
providers in Alaska are poised to assume the care of
prostate cancer survivors locally but with specialty back-
up. Nevertheless, large minorities of providers  some of
whom are the sole provider for hundreds of miles around
 do not feel confident in their ability to manage common
issues in prostate cancer survivorship. Physician turnover
in these positions is high and often includes a number of
physicians who just completed their training. Rigorous
testing of health care delivery interventions including
telemedicine and Continuing Medical Education (CME)
trainings that link local patients and primary care pro-
viders to specialists as well as care delivery innovations
that incentivize high quality survivorship care may be
sustainable and plausible ways to improve care for remote
communities in a cost effective manner. Further research
to test such models may be warranted.
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